25 May 2023	Heidelberg Pharma reports on the results of the Annual General Meeting 2023	PDF	Read More
05 May 2023	PR: Heidelberg Pharma appoints Chief Financial Officer	PDF	Read More
13 April 2023	PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023	PDF	Read More
04 April 2023	PR: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023	PDF	Read More
24 March 2023	PR: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business	PDF	Read More
16 December 2022	PR: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform	PDF	Read More
14 December 2022	PR: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022	PDF	Read More
10 November 2022	PR: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022	PDF	Read More
07 November 2022	PR: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study	PDF	Read More
13 October 2022	PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022	PDF	Read More
04 October 2022	AH: Heidelberg Pharma AG Announces Adjustment of Guidance	PDF	Read More
09 September 2022	AH: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate	PDF	Read More
30 August 2022	PR: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure	PDF	Read More
12 August 2022	PR: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million	PDF	Read More
13 July 2022	AH: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate	PDF	Read More
12 July 2022	PR: Heidelberg Pharma Reports on First Half-Year 2022	PDF	Read More
28 June 2022	PR: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022	PDF	Read More
09 May 2022	AH: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure	PDF	Read More
28 April 2022	PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022	PDF	Read More
07 April 2022	PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022	PDF	Read More
24 March 2022	PR: Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update	PDF	Read More
10 March 2022	PR: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117	PDF	Read More
28 February 2022	PR: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment	PDF	Read More
27 February 2022	AH: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment	PDF	Read More
17 February 2022	AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini	PDF	Read More
15 February 2022	PR: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma	PDF	Read More
28 October 2021	PR: Heidelberg Pharma Participates at Various Conferences	PDF	Read More
07 October 2021	PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021	PDF	Read More
01 October 2021	PR: Heidelberg Pharma AG Announces Adjustment of Guidance	PDF	Read More
09 September 2021	PR: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences	PDF	Read More

Press Releases and Ad-hoc Announcements